<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363181</url>
  </required_header>
  <id_info>
    <org_study_id>F1DMC-X280</org_study_id>
    <nct_id>NCT00363181</nct_id>
  </id_info>
  <brief_title>Side Effects of Antipsychotic Medications</brief_title>
  <official_title>Does Olanzapine Inhibit the Secretory Response to Insulin Resistance?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medications like olanzapine have been associated with the development of weight gain and&#xD;
      diabetes in some patients. It is not known if the increased risk of developing diabetes is a&#xD;
      direct effect on insulin or simply related to weight gain.&#xD;
&#xD;
      We hope to learn in this study whether or not olanzapine directly slows down insulin&#xD;
      secretion from the pancreas, thereby increasing the risk of developing diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: The use of atypical antipsychotics has been associated with increased weight&#xD;
      gain, the development of type-2 diabetes, and, in rare cases, diabetic ketoacidosis. It is&#xD;
      not clear if these changes are a direct function of antipsychotics on either insulin action&#xD;
      or insulin secretion, or simply related to their ability to induce weight gain in a&#xD;
      population at increased risk to develop hyperglycemia. The objective of this investigation is&#xD;
      to determine if treatment with the atypical antipsychotics olanzapine impairs the ability of&#xD;
      the pancreatic beta cell to increase its insulin secretory response to graded increases in&#xD;
      plasma glucose concentration in non-diabetic, insulin resistant individuals. In addition, we&#xD;
      will compare the range of insulin-mediated glucose uptake (IMGU) in olanzapine-treated versus&#xD;
      non-antipsychotic treated patients.&#xD;
&#xD;
      Research Plan and Methods: 120 subjects with psychiatric disorders will be enrolled; 60&#xD;
      patients on olanzapine and 60 patients with similar psychiatric diagnoses on a different&#xD;
      antipsychotic medication (ziprasidone, risperidone or aripiprazole). All subjects will have a&#xD;
      fasting plasma glucose concentration &lt;126 mg/dL, and on no medication with a direct effect on&#xD;
      IMGU. Subjects will be admitted to the General Clinical Research Center (GCRC) at Stanford&#xD;
      Medical Center and evaluated by an insulin suppression test (IST) to determine their IMGU.&#xD;
      Subjects with a steady state plasma glucose (SSPG) concentration during the IST that is &gt;180&#xD;
      mg/dL will be defined as being insulin resistant. From this population of subjects, 15&#xD;
      patients on olanzapine and 15 patients not on any antipsychotic, will return to the GCRC to&#xD;
      determine their glucose-stimulated insulin secretory dose-response curves (GS-ISR). The&#xD;
      GS-ISR at the same glucose concentration will be compared between the subjects on olanzapine&#xD;
      (n=15) and the not on an antipsychotic (n=15) by analysis of variance. Analyses of the 120&#xD;
      subjects screened for insulin resistance will compare 1) the means and distribution of the&#xD;
      SSPG concentrations in olanzapine and non-olanzapine treated patients with psychiatric&#xD;
      diagnoses; and 2) the means of the two experimental groups with psychiatric diagnoses to Dr.&#xD;
      Reaven's data base of volunteers without psychiatric disorders.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">76</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Metabolic Syndrome X</condition>
  <condition>Schizophrenia and Disorders With Psychotic Features</condition>
  <condition>Mood Disorders</condition>
  <condition>Psychotic Disorders</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants 30-66 years of age&#xD;
&#xD;
          -  Body mass index (BMI) &gt;25 &lt; 35 kg/m2.&#xD;
&#xD;
          -  Fasting plasma glucose concentration &lt; 126 mg/dL&#xD;
&#xD;
          -  Stable on one of the following psychiatric medication: Olanzapine (Zyprexa速),&#xD;
             Ziprasidone (Geodon速), Aripiprazole (Abilify速), or Risperidone (Risperdal速)&#xD;
&#xD;
          -  Stable on psychiatric medication for at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medications that directly affect insulin-mediated glucose disposal&#xD;
&#xD;
          -  Intense suicidal impulses/intent&#xD;
&#xD;
          -  Alcohol or substance abuse for 3 months.&#xD;
&#xD;
          -  Major medical problems, i.e., clinically unstable medical disorder or condition;&#xD;
             cardiovascular, hepatic, renal, gastrointestinal, pulmonary, endocrine or other&#xD;
             systemic disease that would, in the investigator's clinical judgment interfere with&#xD;
             the endocrine measures obtained in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven E Lindley, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford School of Medicine / VA Palo Alto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerald M Reaven, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 9, 2006</study_first_submitted>
  <study_first_submitted_qc>August 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin resistance</keyword>
  <keyword>Metabolic problems</keyword>
  <keyword>Weight gain</keyword>
  <keyword>Mental health problems</keyword>
  <keyword>Mental disorders</keyword>
  <keyword>Antipsychotic medication</keyword>
  <keyword>Olanzapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
    <mesh_term>Schizophrenia Spectrum and Other Psychotic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

